Amyris Provides Update to Investors, but Not the Numbers Needed
It seems pretty certain that the coronavirus pandemic will cause a recession in the United States and globally. It's a little too soon to know whether the economic fallout will expose the flaws in Silicon Valley's growth-at-all-costs and debt-binging funding models. If such a reckoning takes place, then the hype-driven field of synthetic biology is in a pretty poor position.
Take Amyris (NASDAQ: AMRS) as an example. It issued full-year 2019 operating results last week that spooked investors. It's impossible to tease out exactly how much of the tumble was due to macro concerns, and how much was due to company-specific anxieties, but investors don't seem to be running into the plunging small-cap stock.
When the company issued an update in an attempt to clarify the latest results and add more detail, it didn't quite help. Again, the broader market is falling, but Amyris still hasn't published the numbers investors actually need to see.
Source Fool.com
